Cambridge Trust’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Cambridge Trust’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-18,175	Closed	-$76K	–	256
2018 Q3	$76K	Hold	18,175	–	–	﹤0.01%	245
2018 Q2	$70K	Hold	18,175	–	–	﹤0.01%	242
2018 Q1	$115K	Hold	18,175	–	–	0.01%	246
2017 Q4	$147K	Hold	18,175	–	–	0.01%	254
2017 Q3	$208K	Sell	18,175 -1	-0%	-$11	0.01%	247
2017 Q2	$177K	Hold	18,176	–	–	0.01%	243
2017 Q1	$440K	Hold	18,176	–	–	0.03%	191
2016 Q4	$583K	Hold	18,176	–	–	0.04%	170
2016 Q3	$908K	Hold	18,176	–	–	0.07%	134
2016 Q2	$771K	Hold	18,176	–	–	0.06%	137
2016 Q1	$1.2M	Hold	18,176	–	–	0.1%	109
2015 Q4	$1.13M	Hold	18,176	–	–	0.09%	108
2015 Q3	$1.22M	Hold	18,176	–	–	0.11%	108
2015 Q2	$1.77M	Sell	18,176 -1,271	-7%	-$121K	0.15%	96
2015 Q1	$1.82M	Sell	19,447 -1,525	-7%	-$130K	0.15%	95
2014 Q4	$1.86M	Sell	20,972 -1,906	-8%	-$139K	0.16%	95
2014 Q3	$1.58M	Hold	22,878	–	–	0.14%	92
2014 Q2	$1.31M	Sell	22,878 -5,084	-18%	-$258K	0.11%	100
2014 Q1	$1.11M	Sell	27,962 -1,271	-4%	-$54.4K	0.1%	103
2013 Q4	$1.23M	Sell	29,233 -509	-2%	-$14.8K	0.11%	99
2013 Q3	$887K	Sell	29,742 -635	-2%	-$22.2K	0.09%	108
2013 Q2	$1.61M	Buy	+30,377	New	+$1.33M	0.17%	85

Other funds holding MACK

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Sepio Capital Salt Lake City, Utah $1.84B AUM 18.57% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

WIM

Wittenberg Investment Management Carlisle, Massachusetts $269M AUM 28.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Cambridge Trust's MACK Position: Q4 2018 in Review

Cambridge Trust sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q4 2018, closing a stake of 18,175 shares — an estimated $76K sold.

Cambridge Trust first reported a position in MACK in Q2 2013 and held it in 22 quarters. The position peaked at $1.86M in Q4 2014. 56 funds tracked by Wall St. Rank hold MACK as of Q4 2018.

Cambridge Trust reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
Cambridge Trust sold 18,175 Merrimack Pharmaceuticals, Inc. shares in Q4 2018, an estimated $76K.
Cambridge Trust first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2013 and held it in 22 quarters.
Cambridge Trust's Merrimack Pharmaceuticals, Inc. position peaked at $1.86M in Q4 2014.
56 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q4 2018.

Based on Cambridge Trust's 13F filing for Q4 2018, filed 4 Feb 2019.